AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 2.47
(8.33%)
SEK 2.47
(8.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.86 Million SEK | 31.97% |
| 2022 | -55.66 Million SEK | 27.9% |
| 2021 | -77.2 Million SEK | -8.94% |
| 2020 | -70.87 Million SEK | -40.56% |
| 2019 | -50.56 Million SEK | -40.88% |
| 2018 | -36.03 Million SEK | -232.64% |
| 2017 | -10.81 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.78 Million SEK | 11.46% |
| 2024 Q1 | -9.69 Million SEK | -0.51% |
| 2023 Q4 | -9.92 Million SEK | -31.6% |
| 2023 FY | - SEK | 32.04% |
| 2023 Q3 | -7.54 Million SEK | 25.15% |
| 2023 Q2 | -10.08 Million SEK | -7.09% |
| 2023 Q1 | -9.41 Million SEK | 12.94% |
| 2022 FY | - SEK | 27.9% |
| 2022 Q3 | -10.95 Million SEK | 48.82% |
| 2022 Q2 | -21.4 Million SEK | -71.19% |
| 2022 Q1 | -12.5 Million SEK | 44.38% |
| 2022 Q4 | -10.81 Million SEK | 1.28% |
| 2021 Q2 | -15.53 Million SEK | 31.99% |
| 2021 FY | - SEK | -8.94% |
| 2021 Q1 | -22.83 Million SEK | -29.88% |
| 2021 Q4 | -22.47 Million SEK | -37.36% |
| 2021 Q3 | -16.36 Million SEK | -5.34% |
| 2020 Q1 | -13.67 Million SEK | 11.9% |
| 2020 Q2 | -18.28 Million SEK | -33.74% |
| 2020 FY | - SEK | -40.56% |
| 2020 Q4 | -17.58 Million SEK | 17.54% |
| 2020 Q3 | -21.32 Million SEK | -16.61% |
| 2019 FY | - SEK | -40.88% |
| 2019 Q4 | -15.52 Million SEK | -16.7% |
| 2019 Q3 | -13.3 Million SEK | -30.15% |
| 2019 Q2 | -10.21 Million SEK | 10.78% |
| 2019 Q1 | -11.45 Million SEK | 10.75% |
| 2018 Q1 | -9.61 Million SEK | -69.82% |
| 2018 FY | - SEK | -232.64% |
| 2018 Q4 | -12.83 Million SEK | -127.74% |
| 2018 Q3 | -5.63 Million SEK | 26.91% |
| 2018 Q2 | -7.71 Million SEK | 19.79% |
| 2017 Q3 | -51 Thousand SEK | 0.0% |
| 2017 Q4 | -5.66 Million SEK | -10998.04% |
| 2017 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -176.59% |
| BioGaia AB (publ) | 466.19 Million SEK | 108.123% |
| Enzymatica AB (publ) | -41.12 Million SEK | 7.913% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 12.043% |
| Gabather AB (publ) | 37 Thousand SEK | 102445.946% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -156.385% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | -40.463% |
| Nanexa AB (publ) | -70.79 Million SEK | 46.507% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -206.872% |
| ODI Pharma AB | 1.36 Million SEK | 2869.418% |
| Orexo AB (publ) | -22 Million SEK | -72.127% |
| Probi AB (publ) | 115.61 Million SEK | 132.754% |
| Swedencare AB (publ) | 484 Million SEK | 107.824% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.523% |
| Toleranzia AB | -7.39 Million SEK | -411.868% |
| Vivesto AB | -89.75 Million SEK | 57.811% |